Search

Search Constraints

You searched for: Author/Creator Yi, Min

Search Results

2. 433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial. (10th December 2020)

8. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Issue 8 (30th June 2022)